Baseline demographics and patient characteristics
| Characteristics | Ipilimumab (N=9) | Ipilimumab plus nivolumab (N=10) | Total (N=19) |
| Age (year), median (range) | 66 (35–83) | 56 (39–66) | 60 (35–83) |
| Sex, n (%) | |||
| Male | 6 (67) | 9 (90) | 15 (79) |
| Female | 3 (33) | 1 (10) | 4 (21) |
| Race, n (%) | |||
| Asian | 0 | 1 (10) | 1 (5) |
| White | 9 (100) | 7 (70) | 16 (84) |
| Other | 0 | 2 (20) | 2 (11) |
| Eastern Cooperative Oncology Group performance status score, n (%) | |||
| 0 | 6 (67) | 7 (70) | 13 (68) |
| 1 | 3 (33) | 3 (30) | 6 (32) |
| M stage, n (%) | |||
| M0 | 3 (33) | 1 (10) | 4 (21) |
| M1a | 1 (11) | 2 (20) | 3 (16) |
| M1b | 2 (22) | 3 (30) | 5 (26) |
| M1c without brain metastases | 3 (33) | 4 (40) | 7 (37) |
| Type of melanoma, n (%) | |||
| Acral | 1 (11) | 1 (10) | 2 (11) |
| Cutaneous | 7 (89) | 8 (90) | 17 (90) |
| Mucosal | 1 (11) | 1 (10) | 2 (11) |
| Lactate dehydrogenase (unit/L), median (range) | 208 (152–1800) | 214 (157–310) | 211.0 (152–1800) |
| Genomic driver | |||
| BRAF | 2 (22) | 3 (30) | 5 (26) |
| NRAS | 4 (44) | 2 (20) | 6 (32) |
| Other/unknown | 3 (33) | 5 (50) | 8 (42) |
| Prior treatment, n (%) | |||
| Anti-PD-1 | 9 (100) | 10 (100) | 19 (100) |
| Other* | 1 (11) | 3 (30) | 4 (21) |
| Time since last anti-PD-1 treatment (weeks), median (range) | 6.0 (3–55) | 4.3 (2–36) | 5.1 (2.0–54.7) |
| Best response to prior anti-PD-1 treatment, n (%) | |||
| Stable disease | 1 (11) | 0 | 1 (5) |
| Progressive disease | 6 (67) | 9 (90) | 15 (79) |
| Unknown | 2 (22) | 1 (10) | 3 (16) |
*Other prior treatments include talimogene laherparepvec (patient randomized to ipilimumab), high-dose interferon, dabrafenib plus trametinib, and vemurafenib plus cobimetinib.
PD-1, programmed death 1.